OettingerWilson Sonsini Goodrich & RosatiProfessional Corporation650 Page Mill RoadPalo Alto, California 94304(650) 493-9300Approximate date of commencement of proposed sale to the public:As soon as practicable after the effective date of this Registration Statement.If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
common stock issuable upon conversion of the Series B convertible preferred stock and upon exercise of the warrants issued hereunder, collectively, as the securities.Our common stock is listed on the Nasdaq Capital Market under the symbol "AVGR." On February 7, 2018, the last reported sales price of our common stock was $4.23 per share.
"Offering").Under the terms of such agreement, the holders of the Series A preferred stock would be entitled to receive annual accruing dividends at a rate of 8%, payable in additional shares
The amount of such increase has not been determined, but could equal up to4Table of Contents20% or more of our total number of shares outstanding or issuable after this offering, including shares issuable upon the exercise of options and warrants or conversion of preferred stock into common
additional financing when needed could force us to delay, reduce or eliminate our product development programs and commercialization efforts or cause us to become insolvent;•We have a significant amount of debt, which may affect our ability to operate our business and secure additional financing in the future;•Nasdaq may delist our securities from its exchange, which could harm our business and limit our stockholders' liquidity;•Our quarterly and annual results may fluctuate significantly, may not fully reflect the underlying performance of our business and may result
in decreases in the price of our common stock;•We have a history of net losses and we may not be able to achieve or sustain profitability;•Our limited commercialization experience and number of approved products makes it difficult to evaluate our current business, predict our
disagree;•The offering price will be set by our board of directors and does not necessarily indicate the actual or market value of our common stock;6Table of Contents•The Series B Preferred Stock and the warrants are unlisted securities and there is no public market for these securities; and•The warrants may not have any value.Company InformationWe were incorporated in Delaware on March 8, 2007.
become available under our ESPP pursuant to provisions thereof that automatically increase the share reserve under the plan each year;•shares of common stock issuable under the Purchase Agreement with Lincoln Park, including the 23,584 Shares we issued as a commitment fee to
as otherwise indicated, all information in this prospectus assumes:•a 1-for- 40 reverse stock split of our common stock, which became effective as of January 30, 2018;•no additional issuances of common stock to Lincoln Park under the Purchase Agreement; and•no exercise of options or warrants outstanding as of the date of this prospectus.12Table of ContentsRISK FACTORSInvesting in our securities involves a high degree of risk.
performance of our business and may result in decreases in the price of our common stock.Our quarterly and annual results of operations, including our revenues, profitability and cash flow, may vary significantly in the future and
clearances and approvals, particularly with respect to current and future generations of Pantheris;•market acceptance of our Lumivascular platform and products, including Pantheris;•the availability of reimbursement for our Lumivascular platform products;•our ability to attract new customers and increase the amount of business we generate from existing customers;•results of our clinical trials;•the timing and success of new product and feature introductions by us or our competitors or any other change in the competitive dynamics of our
industry, including consolidation among competitors, customers or strategic partners;•the amount and timing of costs and expenses related to the maintenance and expansion of our business and operations;•changes in our pricing policies or those of our competitors;•general economic, political, industry and market conditions, including economic and political uncertainty caused by the recent U.S. presidential election;•the regulatory environment;•the hiring, training and retention of key employees, including our sales team;•the ability of our remaining sales and marketing personnel to maintain and increase our revenues after the April 2017 organizational
described below under "Risks Related to Ownership of our13Table of ContentsCommon Stock—Our stock price may be volatile, and purchasers of our common stock could incur substantial losses.";•our ability to obtain additional financing; and•advances and trends in new technologies and industry standards.We have a history of net losses and we may not be able to achieve or sustain profitability.We have incurred significant losses in each period since our inception in 2007.
Our failure to achieve and sustain profitability would negatively impact the market price of our common stock.We may not be able to secure additional financing on favorable terms, or at all, to meet our future capital
Given the recent decline in our stock price, any financing that we undertake in the next nine months could cause substantial dilution to our existing stockholders.To date, we have financed our operations primarily through sales of our products and net proceeds from the issuance of our preferred stock and debt financings, our "at-the-market"
versions of such products;•the costs, timing and outcomes of clinical trials and regulatory reviews associated with our future products;•the costs and expenses of maintaining or expanding our sales and marketing infrastructure and our manufacturing operations;•the costs and timing of developing variations of our Lumivascular platform products, especially Pantheris and, if necessary, obtaining FDA
interventional radiologists in the treatment of PAD;•the number and types of future products we develop and commercialize;•the costs of defending ourselves against existing and future litigation, including pending stockholder class action claims;•the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related
Our significant amount of debt may:•make it more difficult for us to satisfy our obligations with respect to the Loan Agreement;•increase our vulnerability to adverse changes in general economic, industry and competitive conditions;15Table of Contents•require us to dedicate a substantial portion of our cash flow from operations to make payments on our debt, thereby reducing the availability
of our cash flow to fund working capital, capital expenditures and other general corporate purposes;•limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate;•restrict us from exploiting business opportunities;•make it more difficult to satisfy our financial obligations, including payments on the Loan Agreement•place us at a competitive disadvantage compared to our competitors that have less debt obligations; and•limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions, debt service requirements, execution of
covenants contained in the Loan Agreement could adversely affect our ability to:•finance our operations;•make needed capital expenditures;•make strategic acquisitions or investments or enter into alliances;•withstand a future downturn in our business or the economy in general;•refinance our outstanding indebtedness prior to maturity;•engage in business activities, including future opportunities, that may be in our interest; and•plan for or react to market conditions or otherwise execute our business strategies.We
not address these risks successfully, our operating and financial results could differ materially from our expectations and our business could suffer.Our success depends in large part on a limited number of products, particularly Pantheris, all of which have
operations and use cash, which could reduce our cash faster than budgeted, cause us to need to obtain additional financing and have a material adverse effect on our operations and stock price.21Table of ContentsOur ability to compete is highly dependent on demonstrating the benefits of our Lumivascular platform to
sub-assemblies incorporated into our products would limit our ability to manufacture our products and could therefore harm our business, financial condition and results of operations.Our future growth depends on physician adoption of our Lumivascular platform products, which may require
products, or if clearances or approvals for future products and indications are delayed or not issued, our commercial operations would be harmed.Our Lumivascular platform products are medical devices that are subject to extensive regulation by FDA in the United States and by regulatory
The market price for our common stock may be influenced by many factors, including:•sales of stock by our existing stockholders, including our affiliates;•market acceptance of our Lumivascular platform and products, including Pantheris;•the results of our clinical trials;•changes in analysts' estimates, investors' perceptions, recommendations by securities analysts or our failure to achieve analysts' and our own
operating results fail to meet the forecast of analysts, our stock price will likely decline.40Table of ContentsSales of a substantial number of shares of our common stock in the public market, including by our existing
an "at-the-market" program pursuant to a Sales Agreement with Cowen, through which we issued and sold approximately 0.2 million shares of common stock having an aggregate offering value of
During the nine months ended September 30, 2017, we sold 0.2 million shares of common stock through the "at-the-market" program at an average price of $17.68 and raised net proceeds of
transaction expenses and the number of shares required to be sold to finance our operations.In addition, pursuant to our Securities Purchase Agreement with CRG, the Shelf Registration Statement also registered for resale 8,705 shares of common stock held by CRG, which may be
The terms of this relief require that, by March 31, 2018, we:•achieve a closing bid price of $1.00 or more for a minimum of ten consecutive trading days;•effect a conversion of part of our debt with CRG into preferred equity;•issue disclosure that our stockholders' equity is above $2.5 million; and•provide Nasdaq with updated financial projections demonstrating our ability to maintain compliance through the end of fiscal year 2018.We are diligently working to evidence compliance with all applicable Nasdaq listing criteria; however, there can be no assurance that we will be able to achieve all elements of our
These forward-looking statements include, but are not limited to, statements about:•the outcome of and expectations regarding our current clinical studies and any additional clinical studies we initiate;•our plans to modify our current products, or develop new products, to address additional indications;•our ability to obtain additional financing through future equity or debt financings;•the expected timing of 510(k) submission to FDA, and associated marketing clearances by FDA, for enhanced versions of Pantheris;•the expected growth in our business and our organization;•our expectations regarding government and third-party payor coverage and reimbursement, including the ability of Pantheris to qualify for
September 2017 cost reduction plan;•our ability to obtain and maintain intellectual property protection for our products;•our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for, or ability to obtain, additional
administrative expenses;•our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act;•our ability to identify and develop new and planned products and acquire new products;•our financial performance;•our ability to remain in compliance with laws and regulations that currently apply or become applicable to our business, both in the United
preferred stock, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.You should read this table together with "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this prospectus.
become available under our ESPP pursuant to provisions thereof that automatically increase the share reserve under the plan each year;•shares of common stock issuable under the Purchase Agreement with Lincoln Park, including the 23,584 Shares we issued to Lincoln Park as a
We expect our current manufacturing facility will be sufficient through at least 2019.In addition to commercialization of Pantheris in the United States and select international markets in March 2016, we began commercializing our initial non-Lumivascular platform products
to a Sales Agreement with Cowen and Company, or Cowen, through which we may, from time to time, issue and sell shares of common stock having an aggregate offering value of up to $50.0 million.
included stock-based compensation expense of $0.7 million compared to $0.9 million for the three months ended September 30, 2017 and 2016, respectively.Restructuring.In September 2017, we effected a cost reduction plan, which included a company-wide reduction in force, lowering our total
development, commercialization and marketing of our products and we may be required to significantly scale back our business and operations.To date, our primary sources of capital have been private placements of preferred stock, debt financing agreements, our "at-the-market" program, our IPO and our follow-on public offering
stock-based compensation, non-cash interest expense and other charges related to our credit agreement with CRG, and an increased reserve for excess and obsolescence in inventories.65Table of ContentsNet Cash Used in Investing ActivitiesNet cash used in investing activities in the nine months ended September 30, 2017 was $41,000 consisting of purchases of property and
Landlord's operating expenses and property taxes due and payable with respect to the subleased facility.There have been no other material changes to our contractual obligations from those described in our Annual Report on Form 10-K, as filed with the SEC on March 14, 2017.66Table of ContentsBUSINESSOverviewWe are a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems that are used by
applicable vesting date.93Table of ContentsThe exercise price per share of each stock option granted under our outside director compensation policy, including Retainer Options, Initial Options and Annual Options, will be the fair
company expenses of approximately $        which includes legal accounting printing costs and various fees associated with the registration of our securities.Determination of Offering PriceOur common stock is currently traded on the Nasdaq Capital Market under the symbol "AVGR." On February 7, 2018 the closing price of our common
December 31, 2016, the Company sold 27,374 shares of common stock under the "at-the-market" program at an average price of $194.74 and raised net proceeds of $5,171,000, after payment of
outstanding principal and accrued and unpaid interest, or (ii) the amount providing the investor with a 20% minimum internal rate of return, at any time prior to their maturity date.In conjunction with the issuance of the convertible notes, the Company issued warrants to purchase up to the number of shares of common stock equal to 15% of the principal amount of the
the Company's Series E Convertible Preferred Stock purchased.F-29Table of ContentsAVINGER, INC.Notes to Financial Statements (Continued)12.
2015.As of December 31, 2016 and 2015, warrants to purchase an aggregate of 53,715 and 54,748 shares of common stock were outstanding, respectively.The Company determined that the amendment to the Series E Convertible Preferred Stock Purchase Agreement should be accounted for as a modification.
and $217,000 in stock-based compensation expense related to the ESPP for the year ended December 31, 2016 and 2015, respectively.F-33Table of ContentsAVINGER, INC.Notes to Financial Statements (Continued)13.
within stockholders' equity (deficit).As of September 30, 2017 and December 31, 2016, warrants to purchase an aggregate of 53,715 shares of common stock were outstanding.F-59Table of ContentsAVINGER, INC.Notes to Condensed Financial Statements (Continued)8.